Kenvue
KVUE
$17.32
-0.17%
Kenvue Inc. is the world's largest pure-play consumer health company, operating in the Household & Personal Products industry. Its portfolio includes iconic over-the-counter and personal care brands such as Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena, serving categories like cough/cold, pain management, oral care, and skin health. The company is a dominant market leader with a vast global footprint, spun off from Johnson & Johnson in May 2023. The overwhelming investor narrative is currently dominated by the pending acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has framed the stock's trading and valuation around the deal's perceived certainty and terms rather than its standalone fundamentals.…
KVUE
Kenvue
$17.32
Related headlines
KVUE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $22.52 and implied upside of +30.0% versus the current price.
Average Target
$22.52
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$14 - $23
Analyst target range
Analyst coverage for Kenvue appears limited, with only 3 analysts providing estimates in the dataset, and institutional ratings show a pattern of Hold or Neutral actions. The consensus sentiment is neutral, as recent actions from firms like Jefferies (downgraded to Hold from Buy in Jan 2026) and Canaccord Genuity (downgraded to Hold from Buy in Oct 2025) indicate a lack of bullish conviction, likely due to the capped upside from the pending acquisition. The average revenue estimate for the next period is $17.30 billion, with a tight range between $17.14B and $17.43B, and average EPS is $1.41, ranging from $1.39 to $1.42. While explicit price targets are not provided in the data, the narrow EPS and revenue estimate ranges suggest analysts have high conviction in near-term financials but see limited stock price catalysts outside the deal. The limited number of analysts and the prevalence of Hold/Neutral ratings reflect the stock's status as an event-driven holding; the primary investment thesis is no longer based on fundamental outperformance but on the successful closure of the Kimberly-Clark acquisition, which removes the need for extensive traditional equity analysis and price target setting.
Bulls vs Bears: KVUE Investment Factors
The investment debate for Kenvue is overwhelmingly dominated by the pending acquisition by Kimberly-Clark, making it a binary event-driven trade rather than a fundamental equity story. The bull case, supported by strong cash flow, iconic brands, and a discounted forward P/E of 13.97x, is entirely contingent on the deal closing. The bear case highlights the severe downside risk if the deal fails, given the stock's -26.72% annual underperformance and lack of standalone growth catalysts. Currently, the bear side has stronger evidence in terms of price action and sentiment, but the bull case is supported by the high probability of deal completion. The single most important tension is the certainty of the acquisition closing versus the risk of it unraveling; the resolution of this binary outcome will completely determine shareholder returns, rendering traditional fundamental analysis secondary.
Bullish
- Pending Acquisition by Kimberly-Clark: The announced acquisition by Kimberly-Clark, expected to close in H2 2026, provides a clear exit event and caps downside risk. The stock's current valuation, with a forward P/E of 13.97x, appears to be pricing in the deal's completion and associated synergies, offering a defined risk/reward profile for arbitrageurs.
- Strong Free Cash Flow Generation: The company generates robust free cash flow, with TTM FCF of $1.72 billion. This strong cash generation supports the current dividend, which yields 4.8%, and provides financial flexibility during the pre-acquisition period, underpinning the stock's stability.
- Dominant Portfolio of Iconic Brands: Kenvue owns a portfolio of leading consumer health brands like Tylenol, Listerine, and Neutrogena. This provides pricing power, evidenced by a healthy TTM gross margin of 58.13%, and creates a stable revenue base with Q4 2025 revenue of $3.78B, up 3.22% YoY.
- Attractive Forward Valuation: The forward P/E of 13.97x represents a significant discount to the trailing P/E of 22.42x and its historical highs above 35x. This discount reflects the acquisition premium and suggests limited standalone downside if the deal proceeds as planned.
Bearish
- Deal Completion Risk & Regulatory Scrutiny: The entire investment thesis hinges on the Kimberly-Clark acquisition closing successfully. Any regulatory hurdles, financing issues, or market shifts that jeopardize the deal could cause the stock to collapse towards its standalone value, represented by the 52-week low of $14.02, a 19% downside from the current price.
- Stagnant Standalone Growth Profile: As a standalone entity, Kenvue exhibits low-single-digit organic growth, with revenue hovering between $3.74B and $3.84B over the last four quarters. This mature profile, with Q4 revenue growth of 3.22%, offers little fundamental upside catalyst outside of the acquisition.
- Significant Underperformance vs. Market: The stock has dramatically underperformed, with a 1-year price change of -26.72% versus the SPY's +28.21% gain, a relative weakness of -54.93%. This long-term downtrend suggests a loss of investor interest in the standalone story and heavy reliance on the acquisition for price support.
- Analyst Downgrades to Hold/Neutral: Recent analyst actions, including downgrades from Jefferies and Canaccord Genuity to Hold, reflect a lack of bullish conviction and a view that upside is capped by the acquisition terms. With only 3 analysts providing estimates, coverage is thin, indicating limited fundamental interest.
KVUE Technical Analysis
Kenvue's stock is in a pronounced long-term downtrend, with a 1-year price change of -26.72% significantly underperforming the broader market (SPY +28.21%). The current price of $17.28 sits approximately 34% above its 52-week low of $14.02 but 28% below its 52-week high of $23.9, positioning it in the lower half of its yearly range. This suggests the stock has experienced substantial de-rating from its post-spinoff highs but has found a tentative base, likely supported by the acquisition announcement. Recent short-term momentum shows a slight uptick, with a 1-month gain of 0.29%, but this is a sharp underperformance against the SPY's 6.31% rally, as indicated by the -6.02 relative strength. The 3-month return of -9.62% confirms the short-term trend remains negative and aligned with the longer-term downtrend, though the slight positive 1-month move could indicate stabilization as the acquisition arbitrage trade develops. Key technical levels are clearly defined, with major resistance at the 52-week high of $23.9 and support at the 52-week low of $14.02. A sustained break below $14.02 would signal a loss of confidence in the deal's completion, while a move above $23.9 seems improbable given the pending acquisition. The stock's beta of 0.521 indicates it is approximately 48% less volatile than the market, a typical characteristic for a large-cap consumer staples company, but this low volatility is currently amplified by the stock trading as a merger arbitrage vehicle, limiting its independent price action.
Beta
0.52
0.52x market volatility
Max Drawdown
-42.3%
Largest decline past year
52-Week Range
$14-$24
Price range past year
Annual Return
-26.8%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -0.6% | +5.4% |
| 3m | -4.8% | +10.9% |
| 6m | +1.9% | +11.0% |
| 1y | -26.8% | +28.1% |
| ytd | +0.0% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Kenvue's revenue growth is stable but modest, with Q4 2025 revenue of $3.78 billion representing a 3.22% year-over-year increase. The quarterly trend shows revenue has hovered between $3.74B and $3.84B over the last four quarters, indicating low-single-digit organic growth typical for its mature categories. Segment data for the latest quarter shows Self Care ($1.59B) as the largest contributor, followed by Essential Health ($1.15B) and Skin Health and Beauty ($1.04B), providing a balanced portfolio. The company is consistently profitable, with Q4 2025 net income of $330 million and a net margin of 8.73%. Gross margins are robust at 58.13% (TTM) and were 56.53% in Q4, reflecting pricing power of its strong brands. However, operating leverage appears mixed; the Q4 operating margin was 17.84%, down from 21.83% in Q2 2025, indicating some quarterly volatility in profitability, though the trailing operating margin of 17.88% remains healthy for the sector. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.79, and a current ratio of 0.96 indicates adequate but not excessive liquidity. Free cash flow generation is strong, with TTM FCF of $1.72 billion, providing ample coverage for its dividend, which had a TTM payout ratio of 107.55%. Return on equity of 13.66% is respectable, suggesting efficient use of shareholder capital. The financial health is solid, supporting the company's ability to operate independently until the acquisition closes.
Quarterly Revenue
$3.8B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.56%
Latest Quarter
Free Cash Flow
$1.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Given Kenvue's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 22.42x, while the forward P/E is significantly lower at 13.97x, indicating the market expects a substantial earnings increase, likely factoring in synergies from the Kimberly-Clark acquisition. The forward P/E of 13.97x suggests the stock is being valued on a post-deal earnings basis rather than its standalone prospects. Comparing to sector peers is challenging without explicit industry averages, but a forward P/E in the mid-teens is typical for stable, large-cap consumer staples, suggesting Kenvue is trading at a discount to its intrinsic value if the deal completes. Historically, Kenvue's own valuation has compressed significantly since its spinoff; its trailing P/E of 22.42x is well below the 35.63x seen in Q1 2025 and the 34.90x from Q4 2024. This compression reflects the stock's transition from a growth narrative post-IPO to a value/arbitrage story tied to the acquisition. The current P/S ratio of 2.18x and EV/Sales of 2.72x also sit below its historical highs, further indicating the stock is priced for the deal's completion rather than for standalone growth.
PE
22.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 20x~148x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Kenvue's primary financial risk is its elevated dividend payout, with a TTM payout ratio of 107.55% indicating dividends are not fully covered by earnings, which could pressure cash reserves if the acquisition timeline extends. Operating margin volatility is a concern, having dropped from 21.83% in Q2 2025 to 17.84% in Q4 2025, suggesting potential cost pressures or mix issues in its mature, low-growth business segments. Revenue concentration in slow-growth consumer health categories limits organic upside, with quarterly revenue growth stabilizing around a modest 3.22% YoY.
Market & Competitive Risks: The paramount market risk is deal breakage, which would likely cause the stock to re-rate to its standalone value, potentially revisiting its 52-week low of $14.02. The stock's valuation has already compressed from a trailing P/E of 35.63x in Q1 2025 to 22.42x today, reflecting its transition to a merger arbitrage vehicle; further compression could occur if interest rates rise and pressure staples multiples. Competitive and regulatory risks are heightened during the acquisition review process, and the stock's low beta of 0.521, while typically defensive, means it offers little protection in a market downturn if the deal premium evaporates.
Worst-Case Scenario: The worst-case scenario is the Kimberly-Clark acquisition failing to receive regulatory approval or being terminated. This would remove the deal premium and force a revaluation based on Kenvue's standalone, low-growth fundamentals. The stock could rapidly fall to its 52-week low of $14.02, representing a -19% decline from the current $17.28, and potentially lower if earnings estimates are cut. A drawn-out regulatory battle or emergence of competing bids could also create significant uncertainty and volatility, exacerbating the downside towards the stock's maximum drawdown level of -42.27% from its highs.
